In a bid to get to Chinese patients faster, Shanghai's I-Mab plans $100M Nasdaq IPO
Aiming to be the next Chinese company to list on Nasdaq after Zai Lab’s debut two years ago, the Shanghai drug developer I-Mab is gunning for a $100 million IPO.
The company — which has raised more than $400 million in the last three years — has a shrewd strategy for biologic development: it first conducts its proof-of-concept trials in the United States and works towards getting FDA clearance for in-human studies. The data generated are then used to advance clinical development in China. Eventually, after the experimental drug has been clinically validated in the United States, the company retains Chinese rights for further development and commercialization — while retaining the option to out-license globally.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.